1. Review the results of a double-blind, randomized trial that assigns patients with type 2 diabetes and albuminuric chronic kidney disease doses of canagliflozin.

2. Look at broader implications

Session date: 
05/02/2019 - 1:00pm to 2:00pm CDT
UCMC W-507
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Saurabh Chawla, MD